J A N U A R Y 2 0 1 9 • O U T PA T I E N T S U R G E R Y. N E T • 3 9
Aries Pharmaceuticals | Eleview
Resection is easier when the target lesion in the GI tract is given a
good lift. That's the idea behind Eleview, a pre-mixed submucosal
injection that's packaged in 10 mL "per-procedure" ampules.
When injected into the submucosa, the composition forms a cushion
of optimal shape and height, says the company, to facilitate the safe
and easy removal of polyps, adenomas and other lesions.
It also provides a longer lasting lift — up to 45 minutes, says the
company — than you'd get with saline alone, or with saline mixed
with methylene blue, so fewer reinjections are needed during the pro-
cedure.
Additionally, the 10 mL ampules mean no more mixing of saline and
methylene blue by the pharmacy, and likely less waste, as a result.
The price, a company rep points out, may actually be comparable
with reprocessing expenses, when you factor in the personnel, chemi-
cals, personal protective equipment, culturing and repair costs associ-
ated with scope reprocessing.
The question is whether physicians will accept the new scope.
Ambu thinks it's addressed that issue with a device that's designed to
be light and ergonomic, easy to manipulate and easy to withdraw.
Above all, it frees users from any worries about cross-contamina-
tion. As a potential augment to a facility's supply of reusable scopes,
it's a natural for patients who test positive for C. diff or other antibiot-
ic-resistant infections, as well as those with compromised immune
systems. And, as the rep points out, if you switch to disposable
scopes toward the end of the work day, you might be able to send
your reprocessing techs home earlier.
